Omeros (OMER) Price/Book Ratio: History & Chart

Omeros Corporation(OMER)

Biotechnology · Seattle, WA

$18.56-0.34 (-1.80%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Seattle, WA

175 employees

www.omeros.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory A. Demopulos

View full financials

NAME	MARKET CAP	PB RATIO	TTM	3Y	5Y
Omeros Corporation (OMER)	$1.34B	N/A	6.40	8.08	6.86
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.33B	2.94	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	29.85	12.45	6.00	4.99
Inhibrx Biosciences Inc. (INBX)vs ›	$1.39B	N/A	42.62	34.40	31.48
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	3.62	7.79	7.53	6.36
The Pennant Group, Inc. (PNTG)vs ›	$1.41B	3.92	3.45	3.95	3.91
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	1.26	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	133.87	103.22	36.11	20.51
Braveheart Bio, Inc. (BRVE)vs ›	$1.43B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.25B	2.03	N/A	N/A	N/A

NAME

MARKET CAP

PB RATIO

TTM

Omeros Corporation (OMER)

$1.34B

N/A

6.40

8.08

6.86

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›

$1.33B

2.94

N/A

Alpha Tau Medical Ltd (DRTS)vs ›

$1.32B

29.85

12.45

6.00

4.99

Inhibrx Biosciences Inc. (INBX)vs ›

$1.39B

N/A

42.62

34.40

31.48

Taysha Gene Therapies, Inc. (TSHA)vs ›

$1.40B

3.62

7.79

7.53

6.36

The Pennant Group, Inc. (PNTG)vs ›

$1.41B

3.92

3.45

3.95

3.91

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.41B

1.26

N/A

AnaptysBio, Inc. (ANAB)vs ›

$1.42B

133.87

103.22

36.11

20.51

Braveheart Bio, Inc. (BRVE)vs ›

$1.43B

N/A

Kardigan, Inc. (KARD)vs ›

$1.25B

2.03

N/A

PB Ratio Formula & Definition

PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)

The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.

PB Ratio FAQ

What is the P/B ratio for Omeros Corporation (OMER)?

The P/B ratio for OMER stock is N/A.

What is the estimated TTM average P/B ratio for Omeros Corporation (OMER)?

The estimated TTM average P/B ratio for OMER stock is 6.40.

What is the estimated 3Y average P/B ratio for Omeros Corporation (OMER)?

The estimated 3Y average P/B ratio for OMER stock is 8.08.

What is the estimated 5Y average P/B ratio for Omeros Corporation (OMER)?

The estimated 5Y average P/B ratio for OMER stock is 6.86.

What is the estimated 10Y average P/B ratio for Omeros Corporation (OMER)?

The estimated 10Y average P/B ratio for OMER stock is 33.13.

What is the estimated 15Y average P/B ratio for Omeros Corporation (OMER)?

The estimated 15Y average P/B ratio for OMER stock is 11.28.

DATE	PB RATIO
2023-11-09	3.86
2023-11-08	3.98
2023-11-07	4.35
2023-11-06	4.17
2023-11-03	3.92
2023-11-02	3.74
2023-11-01	3.46
2023-10-31	3.65
2023-10-30	3.49
2023-10-27	3.31
2023-10-26	3.32
2023-10-25	3.43
2023-10-24	3.80
2023-10-23	3.43
2023-10-20	3.77
2023-10-19	3.86
2023-10-18	4.30
2023-10-17	4.81
2023-10-16	4.72
2023-10-13	6.95
2023-10-12	7.34
2023-10-11	8.04
2023-10-10	8.52
2023-10-09	8.58
2023-10-06	8.49
2023-10-05	8.43
2023-10-04	8.00
2023-10-03	8.24
2023-10-02	8.49
2023-09-29	8.95
2023-09-28	8.95
2023-09-27	8.73
2023-09-26	8.82
2023-09-25	9.16
2023-09-22	9.01
2023-09-21	8.61
2023-09-20	8.98
2023-09-19	9.47
2023-09-18	9.28
2023-09-15	9.53
2023-09-14	9.77
2023-09-13	9.74
2023-09-12	10.17
2023-09-11	10.52
2023-09-08	10.32
2023-09-07	10.40
2023-09-06	10.60
2023-09-05	10.51
2023-09-01	10.85
2023-08-31	10.60
2023-08-30	11.18
2023-08-29	11.46
2023-08-28	11.06
2023-08-25	11.67
2023-08-24	10.78
2023-08-23	11.70
2023-08-22	11.37
2023-08-21	11.15
2023-08-18	10.81
2023-08-17	10.72
2023-08-16	10.85
2023-08-15	11.43
2023-08-14	12.22
2023-08-11	13.17
2023-08-10	12.87
2023-08-09	4.95
2023-08-08	4.86
2023-08-07	4.56
2023-08-04	4.88
2023-08-03	4.80
2023-08-02	4.52
2023-08-01	4.77
2023-07-31	4.97
2023-07-28	4.99
2023-07-27	4.97
2023-07-26	5.04
2023-07-25	5.64
2023-07-24	5.88
2023-07-21	6.06
2023-07-20	6.13
2023-07-19	6.51
2023-07-18	6.10
2023-07-17	5.87
2023-07-14	5.90
2023-07-13	5.82
2023-07-12	5.99
2023-07-11	5.92
2023-07-10	6.19
2023-07-07	6.03
2023-07-06	5.64
2023-07-05	5.83
2023-07-03	6.00
2023-06-30	6.22
2023-06-29	6.07
2023-06-28	6.53
2023-06-27	6.30
2023-06-26	6.18
2023-06-23	6.28
2023-06-22	6.53
2023-06-21	6.67
2023-06-20	7.19
2023-06-16	6.83
2023-06-15	6.83
2023-06-14	6.94
2023-06-13	7.21
2023-06-12	7.33
2023-06-09	8.58
2023-06-08	8.66
2023-06-07	8.06
2023-06-06	8.10
2023-06-05	8.30
2023-06-02	8.47
2023-06-01	8.33
2023-05-31	7.09
2023-05-30	6.69
2023-05-26	6.61
2023-05-25	6.54
2023-05-24	7.09
2023-05-23	7.03
2023-05-22	7.31
2023-05-19	7.16
2023-05-18	6.60
2023-05-17	6.79
2023-05-16	6.08
2023-05-15	6.16
2023-05-12	6.53
2023-05-11	6.26
2023-05-10	6.93
2023-05-09	3.66
2023-05-08	3.66
2023-05-05	3.75
2023-05-04	3.64
2023-05-03	3.60
2023-05-02	3.63
2023-05-01	4.15
2023-04-28	4.25
2023-04-27	4.27
2023-04-26	4.09
2023-04-25	4.23
2023-04-24	4.48
2023-04-21	4.15
2023-04-20	3.82
2023-04-19	4.29
2023-04-18	4.50
2023-04-17	4.47
2023-04-14	4.65
2023-04-13	4.62
2023-04-12	4.11
2023-04-11	4.16
2023-04-10	3.77
2023-04-06	3.51
2023-04-05	3.26
2023-04-04	3.35
2023-04-03	3.38
2023-03-31	3.41
2023-03-30	3.25
2023-03-29	3.32
2023-03-28	3.03
2023-03-27	2.95
2023-03-24	2.83
2023-03-23	2.70
2023-03-22	2.63
2023-03-21	2.62
2023-03-20	2.38
2023-03-17	2.59
2023-03-16	2.88
2023-03-15	2.75
2023-03-14	2.76
2022-05-10	7.15
2022-05-09	7.26
2022-05-06	7.76
2022-05-05	8.13
2022-05-04	9.21
2022-05-03	8.68
2022-05-02	8.86
2022-04-29	9.13
2022-04-28	9.94
2022-04-27	10.23
2022-04-26	10.52
2022-04-25	11.39
2022-04-22	10.81
2022-04-21	10.81
2022-04-20	11.34
2022-04-19	12.36
2022-04-18	12.34
2022-04-14	13.52
2022-04-13	14.55
2022-04-12	13.94
2022-04-11	14.23
2022-04-08	15.10
2022-04-07	15.57
2022-04-06	15.89
2022-04-05	16.02
2022-04-04	16.52
2022-04-01	15.89
2022-03-31	15.81
2022-03-30	15.94
2022-03-29	16.70
2022-03-28	15.84
2022-03-25	16.31
2022-03-24	16.20
2022-03-23	15.78
2022-03-22	16.34
2022-03-21	15.97
2022-03-18	17.23
2022-03-17	16.78
2022-03-16	15.99
2022-03-15	15.28
2022-03-14	14.70
2022-03-11	16.05
2022-03-10	17.02
2022-03-09	18.33
2022-03-08	16.10
2022-03-07	16.41
2022-03-04	16.81
2022-03-03	16.99
2022-03-02	17.97
2019-05-09	1.40
2019-05-08	1.39
2019-05-07	1.35
2019-05-06	1.48
2019-05-03	1.48
2019-05-02	1.45
2019-05-01	1.44
2019-04-30	1.42
2019-04-29	1.43
2019-04-26	1.42
2019-04-25	1.42
2019-04-24	1.43
2019-04-23	1.43
2019-04-22	1.41
2019-04-18	1.40
2019-04-17	1.43
2019-04-16	1.41
2019-04-15	1.39
2019-04-12	1.39
2019-04-11	1.36
2019-04-10	1.35
2019-04-09	1.34
2019-04-08	1.36
2019-04-05	1.40
2019-04-04	1.38
2019-04-03	1.36
2019-04-02	1.35
2019-04-01	1.30
2019-03-29	1.31
2019-03-28	1.30
2019-03-27	1.30
2019-03-26	1.30
2019-03-25	1.29
2019-03-22	1.27
2019-03-21	1.34
2019-03-20	1.32
2019-03-19	1.32
2019-03-18	1.26
2019-03-15	1.21
2019-03-14	1.22
2019-03-13	1.20
2019-03-12	1.20
2019-03-11	1.23

DATE

PB RATIO

2023-11-09

3.86

2023-11-08

3.98

2023-11-07

4.35

2023-11-06

4.17

2023-11-03

3.92

2023-11-02

3.74

2023-11-01

3.46

2023-10-31

3.65

2023-10-30

3.49

2023-10-27

3.31

2023-10-26

3.32

2023-10-25

3.43

2023-10-24

3.80

2023-10-23

3.43

2023-10-20

3.77

2023-10-19

3.86

2023-10-18

4.30

2023-10-17

4.81

2023-10-16

4.72

2023-10-13

6.95

2023-10-12

7.34

2023-10-11

8.04

2023-10-10

8.52

2023-10-09

8.58

2023-10-06

8.49

2023-10-05

8.43

2023-10-04

8.00

2023-10-03

8.24

2023-10-02

8.49

2023-09-29

8.95

2023-09-28

8.95

2023-09-27

8.73

2023-09-26

8.82

2023-09-25

9.16

2023-09-22

9.01

2023-09-21

8.61

2023-09-20

8.98

2023-09-19

9.47

2023-09-18

9.28

2023-09-15

9.53

2023-09-14

9.77

2023-09-13

9.74

2023-09-12

10.17

2023-09-11

10.52

2023-09-08

10.32

2023-09-07

10.40

2023-09-06

10.60

2023-09-05

10.51

2023-09-01

10.85

2023-08-31

10.60

2023-08-30

11.18

2023-08-29

11.46

2023-08-28

11.06

2023-08-25

11.67

2023-08-24

10.78

2023-08-23

11.70

2023-08-22

11.37

2023-08-21

11.15

2023-08-18

10.81

2023-08-17

10.72

2023-08-16

10.85

2023-08-15

11.43

2023-08-14

12.22

2023-08-11

13.17

2023-08-10

12.87

2023-08-09

4.95

2023-08-08

4.86

2023-08-07

4.56

2023-08-04

4.88

2023-08-03

4.80

2023-08-02

4.52

2023-08-01

4.77

2023-07-31

4.97

2023-07-28

4.99

2023-07-27

4.97

2023-07-26

5.04

2023-07-25

5.64

2023-07-24

5.88

2023-07-21

6.06

2023-07-20

6.13

2023-07-19

6.51

2023-07-18

6.10

2023-07-17

5.87

2023-07-14

5.90

2023-07-13

5.82

2023-07-12

5.99

2023-07-11

5.92

2023-07-10

6.19

2023-07-07

6.03

2023-07-06

5.64

2023-07-05

5.83

2023-07-03

6.00

2023-06-30

6.22

2023-06-29

6.07

2023-06-28

6.53

2023-06-27

6.30

2023-06-26

6.18

2023-06-23

6.28

2023-06-22

6.53

2023-06-21

6.67

2023-06-20

7.19

2023-06-16

6.83

2023-06-15

6.83

2023-06-14

6.94

2023-06-13

7.21

2023-06-12

7.33

2023-06-09

8.58

2023-06-08

8.66

2023-06-07

8.06

2023-06-06

8.10

2023-06-05

8.30

2023-06-02

8.47

2023-06-01

8.33

2023-05-31

7.09

2023-05-30

6.69

2023-05-26

6.61

2023-05-25

6.54

2023-05-24

7.09

2023-05-23

7.03

2023-05-22

7.31

2023-05-19

7.16

2023-05-18

6.60

2023-05-17

6.79

2023-05-16

6.08

2023-05-15

6.16

2023-05-12

6.53

2023-05-11

6.26

2023-05-10

6.93

2023-05-09

3.66

2023-05-08

3.66

2023-05-05

3.75

2023-05-04

3.64

2023-05-03

3.60

2023-05-02

3.63

2023-05-01

4.15

2023-04-28

4.25

2023-04-27

4.27

2023-04-26

4.09

2023-04-25

4.23

2023-04-24

4.48

2023-04-21

4.15

2023-04-20

3.82

2023-04-19

4.29

2023-04-18

4.50

2023-04-17

4.47

2023-04-14

4.65

2023-04-13

4.62

2023-04-12

4.11

2023-04-11

4.16

2023-04-10

3.77

2023-04-06

3.51

2023-04-05

3.26

2023-04-04

3.35

2023-04-03

3.38

2023-03-31

3.41

2023-03-30

3.25

2023-03-29

3.32

2023-03-28

3.03

2023-03-27

2.95

2023-03-24

2.83

2023-03-23

2.70

2023-03-22

2.63

2023-03-21

2.62

2023-03-20

2.38

2023-03-17

2.59

2023-03-16

2.88

2023-03-15

2.75

2023-03-14

2.76

2022-05-10

7.15

2022-05-09

7.26

2022-05-06

7.76

2022-05-05

8.13

2022-05-04

9.21

2022-05-03

8.68

2022-05-02

8.86

2022-04-29

9.13

2022-04-28

9.94

2022-04-27

10.23

2022-04-26

10.52

2022-04-25

11.39

2022-04-22

10.81

2022-04-21

10.81

2022-04-20

11.34

2022-04-19

12.36

2022-04-18

12.34

2022-04-14

13.52

2022-04-13

14.55

2022-04-12

13.94

2022-04-11

14.23

2022-04-08

15.10

2022-04-07

15.57

2022-04-06

15.89

2022-04-05

16.02

2022-04-04

16.52

2022-04-01

15.89

2022-03-31

15.81

2022-03-30

15.94

2022-03-29

16.70

2022-03-28

15.84

2022-03-25

16.31

2022-03-24

16.20

2022-03-23

15.78

2022-03-22

16.34

2022-03-21

15.97

2022-03-18

17.23

2022-03-17

16.78

2022-03-16

15.99

2022-03-15

15.28

2022-03-14

14.70

2022-03-11

16.05

2022-03-10

17.02

2022-03-09

18.33

2022-03-08

16.10

2022-03-07

16.41

2022-03-04

16.81

2022-03-03

16.99

2022-03-02

17.97

2019-05-09

1.40

2019-05-08

1.39

2019-05-07

1.35

2019-05-06

1.48

2019-05-03

1.48

2019-05-02

1.45

2019-05-01

1.44

2019-04-30

1.42

2019-04-29

1.43

2019-04-26

1.42

2019-04-25

1.42

2019-04-24

1.43

2019-04-23

1.43

2019-04-22

1.41

2019-04-18

1.40

2019-04-17

1.43

2019-04-16

1.41

2019-04-15

1.39

2019-04-12

1.39

2019-04-11

1.36

2019-04-10

1.35

2019-04-09

1.34

2019-04-08

1.36

2019-04-05

1.40

2019-04-04

1.38

2019-04-03

1.36

2019-04-02

1.35

2019-04-01

1.30

2019-03-29

1.31

2019-03-28

1.30

2019-03-27

1.30

2019-03-26

1.30

2019-03-25

1.29

2019-03-22

1.27

2019-03-21

1.34

2019-03-20

1.32

2019-03-19

1.32

2019-03-18

1.26

2019-03-15

1.21

2019-03-14

1.22

2019-03-13

1.20

2019-03-12

1.20

2019-03-11

1.23

PB Ratio: N/A

OMER PB Ratio Chart

OMER Average PB Ratio Chart

OMER PB Ratio Metrics

OMER Competitors' PB Ratio

Book Value Analysis

PB Ratio Formula & Definition

PB Ratio FAQ

OMER PB Ratio History

Related Metrics